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Routine Elective Cesarean
Section Is Not Justified for
Women With Mechanical Heart Valves
We congratulate Vitale et al. (1) for providing substantive evidence
for a dose-dependent effect on adverse fetal outcome in pregnan-
cies complicated by maternal warfarin therapy. In the United
Kingdom, warfarin embryopathy is rare (2), and recently reported
cases have occurred almost exclusively in women taking large
(.9 mg) doses of warfarin (3). We agree with Vitale et al. (1) that
the small risk of embryopathy (3.4% in their series), which may be
confined to those requiring .5 mg to maintain an adequate
International Normalized Ratio (INR), should not be used as a
justification for recommending that women with prosthetic valves
be managed with heparin throughout their pregnancy, as some
have suggested (4). Indeed, an increased incidence of valve thrombosis
in pregnant women with mechanical valves (albeit mostly older-
generation prostheses in the mitral position) (5), managed with
subcutaneous heparin versus warfarin, has been reported (6). How-
ever, Vitale et al. (1) have highlighted the risks of spontaneous
miscarriage and stillbirth in warfarin-managed pregnancies and have
demonstrated that this too is dose-dependent.
We have two concerns: First is delivery with only brief (two-
day) discontinuation of warfarin therapy. As Vitale et al. pointed
out, the immature fetal liver may not only lead to over-
anticoagulation of the fetus despite a normal INR in the mother,
but also slow clearance of warfarin by the fetus, leading to
continued anticoagulation for up to 10 days after the mother stops
taking warfarin. Although there were no cases of neonatal hem-
orrhage in this series, despite the fact that warfarin was almost
certainly still present in the fetuses at the time of delivery, the
numbers are small and only three babies in the .5 mg group had
reached full term; second is the policy of routine elective cesarean
section at 38 weeks. We do not agree that elective cesarean section
“reduces the risk of perinatal intracranial hemorrhage in the fetus.”
The arguments have been well rehearsed for other maternal
conditions such as autoimmune thrombocytopenic purpura (7) and
hemophilia carriers (8), when there may be a risk of intracranial
hemorrhage in the baby. Indeed, neonatal intracranial hemorrhage
is described after cesarean section in both conditions, and the
current advice is to recommend vaginal delivery (7,8). Pregnancy
increases the risk of valve thrombosis. The time of greatest risk for
venous thrombosis is immediately after delivery, and cesarean
section further increases the risk up to 25-fold (9). We agree with
Elkayam (5), and it is our policy to discontinue warfarin and start
intravenous heparin, which does not cross the placenta and has a
very short half-life, at 36 weeks in preparation for induction of
labor or cesarean section at 38 weeks. We reserve cesarean section
for the usual obstetric indications. Because Vitale et al. (1) state
that “if the patient [on ,5 mg of warfarin] prefers to have vaginal
delivery, intravenous heparin over the last two weeks of gestation
should be offered as an option,” we assume that they deem this to
be a safe alternative. We would suggest that perhaps the emphasis
should be reversed from routine cesarean section to routine vaginal
delivery.
Catherine Nelson-Piercy, MRCP
Mary Ward, 7th Floor, North Wing
St. Thomas’ Hospital
Lambeth Palace Road
London SE1 7EH
United Kingdom
E-mail: catherine.nelson-piercy@gstt.sthames.nhs.uk
Eric Rosenthal, MRCP
Kate Harding, MRCOG
Susan Bewley, MRCOG
PII S0735-1097(00)00557-X
REFERENCES
1. Vitale N, De Feo M, De Santo LS, Pollice A, Tedesco N, Cotruro M.
Dose-dependent fetal complications of warfarin in pregnant women
with mechanical heart valves. J Am Coll Cardiol 1999;33:1637–41.
2. Sbarouni E, Oakley CM. Outcome of pregnancy in women with valve
prostheses. Br Heart J 1994;71:196–201.
3. Wellesley D, Moore I, Heard M, Keeton B. Two cases of warfarin
embryopathy: a re-emergence of this condition. Br J Obstet Gynaecol
1998;105:805–6.
4. Frewin R, Chisholm M. Anticoagulation of women with prosthetic
heart valves during pregnancy. Br J Obstet Gynaecol 1998;105:683–6.
5. Elkayam U. Pregnancy through a prosthetic heart valve. J Am Coll
Cardiol 1999;33:1642–5.
6. Salazar E, Izaguirre R, Verdejo J, Mutchinick O. Failure of adjusted
doses of subcutaneous heparin to prevent thromboembolic phenomena
in pregnant patients with mechanical cardiac valve prostheses. J Am
Coll Cardiol 1996;27:1698–703.
7. Payne SD, Resnik R, Moore TR, et al. Maternal characteristics and risk
of severe neonatal thrombocytopenia and intracranial haemorrhage in
pregnancies complicated by autoimmune thrombocytopenia. Am J
Obstet Gynecol 1997;177:149–55.
8. Ljung R, Lindgren AC, Petrini P, Tengbron L. Normal vaginal delivery
is to be recommended for haemophilia carrier gravidae. Acta Paediatrica
1994;83:609–11.
9. Greer IA. Venous thromboembolism. In: Boom A, Forbes CD,
Thomas DP, Tuddenham EGD, editors. Haemostasis and Thrombo-
sis. Edinburgh: Churchill Livingstone, 1993.
REPLY
We read with great interest the letter by Nelson-Piercy et al.
regarding our article (1). They gave us the benefit of their
experience.
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